High-potency drugs derived from natural products command a large and growing market share in the pharmaceutical industry. In 2019, revenues at contract
development and manufacturing organizations (CDMOs) related to high-potency active pharmaceutical ingredients (HPAPIs) manufacturing were an estimated $10 billion.
development and manufacturing organizations (CDMOs) related to high-potency active pharmaceutical ingredients (HPAPIs) manufacturing were an estimated $10 billion.
Download this white paper to:
- Learn how the expertise of CDMOs in HPAPI manufacturing is becoming increasingly relevant
- Why clients come to CDMOs at various stages of process design and more!
With over 50 years of experience, we are a forward-thinking,
North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.
© Copyright BIOVECTRA 2022.
All Rights Reserved.